

COMPANION DIAGNOSTICS: TECHNOLOGIES AND MARKETS



BIO077B
November 2013

Marianna Tcherpakov
Project Analyst

ISBN: 1-56965-634-7

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
SCOPE AND FORMAT	2
METHODOLOGY AND INFORMATION SOURCES	3
INTENDED AUDIENCE	3
ANALYST CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL COMPANION DIAGNOSTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL COMPANION DIAGNOSTICS MARKET, 2011-2018 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW, STRUCTURE AND SIGNIFICANCE OF THE COMPANION DIAGNOSTICS INDUSTRY	9
COMPANION DIAGNOSTICS AS A NEW TREND IN PERSONALIZED MEDICINE	9
OVERVIEW	9
PERSONALIZED MEDICINE PRODUCTS OVERVIEW	10
<i>TABLE 1 PERSONALIZED MEDICINE OVERVIEW PRODUCTS</i>	11
PREDISPOSITION TESTS	11
SCREENING TESTS	11
DIAGNOSIS	11
MONITORING TESTS	12
COMPANION DIAGNOSTICS	12
<i>TABLE 2 PERSONALIZED MEDICINE DIAGNOSTIC PRODUCTS BY SEGMENT, 2008-2018 (%)</i>	12
<i>FIGURE 1 PERSONALIZED MEDICINE PRODUCTS BY SEGMENT, 2008-2018 (%)</i>	13
<i>TABLE 3 GLOBAL PERSONALIZED MEDICINE DIAGNOSTICS MARKET, THROUGH 2018 (\$ BILLIONS)</i>	13
<i>TABLE 4 COMPANION DIAGNOSTICS INDUSTRY PRODUCTS, 2013 (%)</i>	14
PARTICIPANTS IN THE COMPANION DIAGNOSTICS INDUSTRY	15
In Vitro Diagnostic, Biomarker and Companion Diagnostics Companies	15
In Vitro Diagnostics Companies	15
Biomarker Research Companies	15
Companion Diagnostics Companies	15
Laboratory Test Services Companies	16
Pharmaceutical Companies	16
Regulatory Entities, Insurance Companies and Healthcare Providers	17
Regulatory Entities	17
Insurance Companies	18
Healthcare Providers	19

TOPIC	PAGE NO.
Patients, Physicians and Public Opinion as Additional Drivers of the Companion Diagnostics Industry	19
Organizations Supporting the Personalized Medicine Approach	21
<i>FIGURE 2 COMPANION DIAGNOSTICS INDUSTRY DRIVERS</i>	21
CHALLENGES AND OBSTACLES TO COMPANION DIAGNOSTICS INDUSTRY DEVELOPMENT	22
<i>FIGURE 3 COMPANION DIAGNOSTICS INDUSTRY CHALLENGES</i>	24
CHAPTER 4 BIOMARKER AND DIAGNOSTICS MARKETS AS THE BASIS FOR THE COMPANION DIAGNOSTICS INDUSTRY	27
BIOMARKER MARKET AS THE BASIS FOR THE COMPANION DIAGNOSTICS INDUSTRY	27
OVERVIEW	27
<i>TABLE 5 BIOMARKER STATISTICS IN THE DRUG DEVELOPMENT PROCESS, 2013 (%)</i>	27
<i>TABLE 6 GLOBAL BIOMARKER MARKET, THROUGH 2015 (\$ BILLIONS)</i>	28
<i>TABLE 7 GLOBAL BIOMARKERS IN VARIOUS RESEARCH AREAS, 2013 (\$ BILLIONS)</i>	29
CANCER BIOMARKERS	29
CARDIOVASCULAR DISEASE BIOMARKERS	30
CENTRAL NERVOUS SYSTEM DISORDERS BIOMARKERS	31
IN VITRO DIAGNOSTICS INDUSTRY AS A FOUNDATION AND DRIVER FOR THE COMPANION DIAGNOSTICS FIELD	31
OVERVIEW	31
<i>TABLE 8 IN VITRO DIAGNOSTICS MARKET BY REGION, 2013 (%)</i>	32
<i>TABLE 9 MAJOR IN VITRO DIAGNOSTICS COMPANIES, 2010 (%)</i>	33
CHAPTER 5 EFFECT OF THE REGULATORY ASPECT, COST AND REIMBURSEMENT POLICIES ON THE COMPANION DIAGNOSTICS INDUSTRY	36
<i>TABLE 10 COMPANION DIAGNOSTICS, ASSOCIATED DRUGS AND REGULATORY APPROVAL STATES, 2013</i>	38
COMPANION DIAGNOSTICS COST AND REIMBURSEMENT POLICIES AS DRIVERS FOR INDUSTRY DEVELOPMENT	39
<i>TABLE 11 COMPANION DIAGNOSTICS COST EXAMPLES, 2013 (\$)</i>	39
<i>TABLE 12 HEALTHCARE SAVINGS DUE TO COMPANION DIAGNOSTICS TESTS, 2013 (\$ MILLIONS)</i>	41
CHAPTER 6 EFFECT OF THE PERSONALIZED MEDICINE TREND ON PRODUCT DEVELOPMENT IN OTHER INDUSTRIES	43
OVERVIEW	43
<i>TABLE 13 PERSONALIZED MEDICINE MARKET BY SEGMENT, 2010 AND 2015 (\$ BILLIONS)</i>	43
NUTRITION AND WELLNESS MARKET	44
<i>TABLE 14 NUTRITION AND WELLNESS MARKET BY SECTOR, 2013 (%)</i>	44
MEDICAL CARE SERVICES AND HEALTH INFORMATION TECHNOLOGY	44
<i>TABLE 15 HEALTHCARE INFORMATION TECHNOLOGY MARKET BY SECTOR, 2010 (%)</i>	45
DIAGNOSTIC AND THERAPEUTIC SECTOR IN PERSONALIZED MEDICINE	47
<i>TABLE 16 DIAGNOSTIC AND THERAPEUTIC MARKET IN PERSONALIZED MEDICINE BY SECTOR, 2013 (%)</i>	47
DIRECT-TO-CONSUMER OR AT-HOME GENETIC TESTS	47
PERSONAL GENOME SEQUENCING	50

TOPIC	PAGE NO.
<i>TABLE 17 PERSONALIZED MEDICINE PRODUCTS ON THE MARKET FOR THE GENERAL PUBLIC, 2013 (%)</i>	51
CHAPTER 7 PATENT APPLICATIONS FOR COMPANION DIAGNOSTICS AND BIOMARKERS	53
OVERVIEW	53
<i>TABLE 18 GLOBAL PATENT APPLICATIONS IN VARIOUS BIOMARKER RESEARCH FIELDS, 2012</i>	54
<i>FIGURE 4 GLOBAL PATENT APPLICATIONS IN VARIOUS BIOMARKER RESEARCH FIELDS, 2012</i>	54
PATENT APPLICATIONS AND GRANTED PATENTS IN THE COMPANION DIAGNOSTICS INDUSTRY	54
POWER3/STEMTRONIX	54
AVEO PHARMACEUTICALS	55
CLARIENT INC.	55
ENTELOS	55
CHAPTER 8 CURRENT TECHNIQUES AND TECHNOLOGIES FOR COMPANION DIAGNOSTICS	57
OVERVIEW	57
<i>TABLE 19 ADVANTAGES AND DISADVANTAGES OF THE MOST COMMON TECHNIQUES FOR COMPANION DIAGNOSTICS, 2013</i>	58
NOVEL TRENDS AND TECHNOLOGIES IN COMPANION DIAGNOSTICS ASSAY DEVELOPMENT	59
DIGITAL PATHOLOGY AND QUANTITATIVE IMMUNOSTAINING	59
IMAGING AS A COMPANION DIAGNOSTICS TEST APPROACH	60
COGNITIVE DIAGNOSTICS AS COMPANION DIAGNOSTICS TESTS	61
PROTEOMICS TECHNOLOGIES AS PLATFORMS FOR COMPANION DIAGNOSTICS DEVELOPMENT	61
METABOLOMIC APPROACH IN COMPANION DIAGNOSTICS ASSAY DEVELOPMENT	62
CHAPTER 9 GENETIC KNOWLEDGE AND CLINICIAN OPINIONS AS DRIVERS FOR THE COMPANION DIAGNOSTICS MARKET	64
OVERVIEW	64
<i>TABLE 20 U.S. PHYSICIANS ORDERING COMPANION DIAGNOSTICS TESTS AS PART OF DIAGNOSIS AND TREATMENT, 2012 (%)</i>	64
<i>TABLE 21 U.S. PHYSICIANS' OPINIONS REGARDING THE WAYS NOVEL DRUGS WITH COMPANION DIAGNOSTICS WILL AFFECT THE USE OF CHEMOTHERAPY TREATMENT, 2012 (%)</i>	65
<i>TABLE 22 U.S. PHYSICIANS' OPINIONS REGARDING VARIOUS ASPECTS OF PERSONALIZED MEDICINE, 2012 (%)</i>	66
CHAPTER 10 COMPANION DIAGNOSTICS INDUSTRY MARKET EVALUATIONQIAGEN	68
OVERVIEW	68
<i>TABLE 23 PARTICIPANTS IN THE COMPANION DIAGNOSTICS MARKET</i>	68
MAJOR COMPANION DIAGNOSTICS MARKET PARTICIPANTS	73
QIAGEN	73
ROCHE DIAGNOSTICS	74
ABBOTT MOLECULAR	74

TOPIC	PAGE NO.
DAKO (AGILENT TECHNOLOGIES)	75
NEWCOMERS IN COMPANION DIAGNOSTICS MARKET	76
LIFE TECHNOLOGIES (THERMO FISHER SCIENTIFIC)	76
GENPROBE (HOLOGIC)	77
ACQUISITION BENEFITS	77
<i>TABLE 24 ACQUISITIONS OF COMPANION DIAGNOSTICS COMPANIES, 2008 TO 2013</i>	78
MAJOR PHARMACEUTICAL COMPANIES FORMING PARTNERSHIPS WITH COMPANION DIAGNOSTICS COMPANIES	78
<i>TABLE 25 PARTNERSHIPS BETWEEN PHARMA AND DIAGNOSTIC COMPANIES, 2009 TO 2013</i>	78
<i>TABLE 26 COMPANION DIAGNOSTICS DEALS BY RESEARCH AREA, 2004-2012 (%)</i>	81
<i>TABLE 27 DEALS IN COMPANION DIAGNOSTICS BY SELECTED PHARMACEUTICAL PARTNERS, 2009-2012</i>	82
MARKET ESTIMATION FOR COMPANION DIAGNOSTICS DEVELOPMENT	82
<i>TABLE 29 GLOBAL COMPANION DIAGNOSTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	84
CHAPTER 11 COMPANION DIAGNOSTICS INDUSTRY OVERVIEW IN DIFFERENT RESEARCH AREAS	86
COMPANION DIAGNOSTICS PRODUCTS IN CANCER	86
OVERVIEW	86
<i>TABLE 30 COMMON COMPANION DIAGNOSTICS TESTS IN CANCER APPLICATIONS, 2013</i>	86
MAIN COMPANION DIAGNOSTICS ASSAYS IN ONCOLOGY DRUG MARKET	88
HER2 TEST	88
Manufacturers of the Her2/neu Assay	89
<i>TABLE 31 MAIN HER2 TESTS, 2013</i>	91
KIRSTEN RAS SARCOMA TEST	93
<i>TABLE 32 KRISTEN RAS SARCOMA TEST MANUFACTURERS, 2010 (\$)</i>	95
EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION TEST	95
ANAPLASTIC LYMPHOMA RECEPTOR TYROSINE KINASE TESTING	97
BRAF TESTING	99
UGT1A1 TEST	99
GENETIC ASSAYS FOR BREAST CANCER PROGNOSIS	100
BRCA1/2	100
BREAST CANCER INDEX AND CANCER TYPE IDENTIFICATION	101
MAMMAPRINT	101
ONCOTYPEDX	101
MAMMOSTRAT	102
BREAST CANCER PROGNOSIS TESTING MARKET ANALYSIS	102
<i>TABLE 33 GLOBAL ONCOTYPEDX AND BRAC ANALYSIS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	103
<i>FIGURE 5 GLOBAL ONCOTYPEDX AND BRAC ANALYSIS MARKET, 2009-2018 (\$ MILLIONS)</i>	103
ADDITIONAL MOLECULAR MARKERS AND PRODUCTS AS COMPANION DIAGNOSTICS FOR DRUG RESPONSE	104
BCR-ABL ANALYSIS FOR GLEEVEC TREATMENT	104
THIOPURINE S-METHYLTRANSFERASE ACTIVITY FOR PURINETHOL/ THIOPURINE/AZATHIOPRINE TREATMENTS	105

TOPIC	PAGE NO.
DEFICIENCY OF DIHYDROPYRIMIDINE DEHYDROGENASE ACTIVITY FOR 5-FLUOROURACIL	105
G6PD DEFICIENCY FOR ELITEK TREATMENT	105
C-KIT FOR GLEEVEC TREATMENT IN STOMACH CANCER	105
CD33 MARKER FOR MYLOTARG TREATMENT	105
CD25 MARKER FOR ONTAK THERAPY	106
INFLUENCE OF CANCER STATISTICS, HEALTHCARE COSTS AND THE DRUG MARKET ON COMPANION DIAGNOSTICS DEVELOPMENT	106
<i>TABLE 34 U.S. CANCER STATISTICS, 2013</i>	106
BREAST CANCER	106
LUNG CACOLORECTAL CANCERNCER	107
COLORECTAL CANCER	107
LEUKEMIA	107
<i>TABLE 35 U.S. ANNUAL HEALTHCARE COST FOR CANCERS, AND THE AMOUNT SPENT ON SCIENTIFIC RESEARCH BY TYPE, 2010 AND 2011 (\$ BILLIONS/\$ MILLIONS)</i>	107
KRISTEN RAS SARCOMA COMPANION DIAGNOSTICS AS AN EXAMPLE FOR NEW HEALTH ECONOMICS MODEL	108
<i>TABLE 36 COST SAVINGS USING KRISTEN RAS SARCOMA COMPANION DIAGNOSTIC TEST IN COLORECTAL CANCER PATIENTS</i>	108
DRUG MARKET'S EFFECT ON COMPANION DIAGNOSTICS PRODUCT DEVELOPMENT	109
<i>TABLE 37 GLOBAL DRUGS ASSOCIATED WITH COMPANION DIAGNOSTIC TESTS, THROUGH 2018 (\$ BILLIONS)</i>	109
HERCEPTIN AND HER2 TEST	109
VECTIBIX AND KRISTEN RAS SARCOMA TEST	110
ERBITUX AND KRISTEN RAS SARCOMA TEST	110
XALKORI AND ANAPLASTIC LYMPHOMA KINASE TEST	110
ZALBORAF AND BRAF TEST	111
PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND THE PHARMACEUTICAL INDUSTRY IN THE ONCOLOGY SECTOR	112
<i>TABLE 38 PARTNERSHIPS BETWEEN PHARMA AND DIAGNOSTICS COMPANIES IN ONCOLOGY, 2009 TO 2013</i>	112
QIAGEN/DXS AND PARTNERSHIPS	114
ALMAC DIAGNOSTICS PARTNERSHIPS	115
ABBOTT DIAGNOSTICS PARTNERSHIPS WITH PFIZER AND GSK	115
DAKO (AGILENT TECHNOLOGIES) PARTNERSHIPS	116
COMPANION DIAGNOSTICS PRODUCT DEVELOPMENT IN ONCOLOGY	117
<i>TABLE 39 COMPANION DIAGNOSTICS IN THE ONCOLOGY MARKET, THROUGH 2018 (\$ MILLIONS)</i>	118
<i>FIGURE 6 COMPANION DIAGNOSTICS IN THE ONCOLOGY MARKET, 2009-2018 (\$ MILLIONS)</i>	118
COMPANION DIAGNOSTIC TESTS ON THE MARKET FOR METABOLIC DISORDERS	118
OVERVIEW	118
<i>TABLE 40 COMPANION DIAGNOSTIC TESTS FOR METABOLIC DISEASES, 2013</i>	119
LAB21	119
ENTELOS	120
LIPOMICS TECHNOLOGIES/METABOLON	120
TETHYS BIOSCIENCE	121
BIOCRATES AG	121

TOPIC	PAGE NO.
GENOMAS	121
PROGNOMIX	122
LIPOPROTEIN RECEPTOR/ATORVASTATIN TESTS	123
PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES, PHARMACEUTICAL COMPANIES AND ACADEMIC INSTITUTIONS IN THE DEVELOPMENT OF COMPANION ASSAYS FOR METABOLIC DISORDERS	124
<i>TABLE 41 COLLABORATIONS BETWEEN COMPANION DIAGNOSTICS COMPANIES, PHARMACEUTICAL COMPANIES AND ACADEMIC INSTITUTIONS, 2008 TO 2013</i>	124
LIPOMICS TECHNOLOGIES (METABOLON)/JOSLIN DIABETES CENTER (HARVARD MEDICAL SCHOOL)	124
GENOMAS/UNIVERSITY OF PUERTO RICO MEDICAL SCIENCE CAMPUS	125
DECODE GENETICS/CELERA (QUEST DIAGNOSTICS)	125
SIEMENS/LABCORP	125
CELGENE CORP (QUEST DIAGNOSTICS)/AGIOS PHARMACEUTICALS	126
MYRIAD GENETICS (RBM)/SANOFI AVENTIS	126
AGAMATRIX/SANOFI-AVENTIS	126
BIOCRATES AG/PFIZER, ALTANA PHARMA	127
MARKET POTENTIAL FOR COMPANION DIAGNOSTICS TESTS IN METABOLIC DISORDERS	127
<i>TABLE 42 U.S. AND GLOBAL DIABETES, HYPERCHOLESTEROLEMIA AND METABOLIC SYNDROME MARKET, 2013 (MILLIONS/\$ BILLIONS)</i>	127
CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN CARDIOVASCULAR DISEASES	128
OVERVIEW	128
<i>TABLE 43 U.S. CARDIOVASCULAR DISEASE AND HEALTHCARE COSTS, 2010 (\$ MILLIONS/\$ BILLIONS)</i>	129
<i>TABLE 44 COMPANION DIAGNOSTICS FOR CARDIOVASCULAR DISEASES, 2013</i>	129
COMPANION DIAGNOSTIC TEST FOR WARFARIN	130
<i>TABLE 45 U.S. WARFARIN TREATMENT, 2010 (MILLIONS/NUMBER)</i>	130
Manufacturers of Companion Diagnostic Tests for Warfarin	130
Nanosphere Inc.	131
AutoGenomics	131
Genmark Diagnostics	131
Kimball Genetics	131
Market Analysis for Warfarin Test Competitors	131
<i>TABLE 46 WARFARIN SENSITIVITY TESTS BY MANUFACTURER, 2009</i>	133
Companion Diagnostics for Plavix	133
Protein C Deficiency Test for Warfarin Sensitivity	133
Genotyping for NAT1 and NAT2 for BiDil Treatment	134
DRUG MARKET ASSOCIATED WITH CARDIOVASCULAR COMPANION DIAGNOSTICS	134
WARFARIN	134
PLAVIX	135
<i>TABLE 47 GLOBAL PLAVIX MARKET, THROUGH 2012 (\$ MILLIONS)</i>	135
PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES AND PHARMACEUTICAL COMPANIES IN CARDIOVASCULAR DISEASE TREATMENTS	137
<i>TABLE 48 PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES, PHARMACEUTICAL COMPANIES AND ACADEMIC INSTITUTIONS IN THE CARDIOVASCULAR DISEASE SECTOR, 2007-2011</i>	137
LABCORP/ARCA BIOPHARMA	137

TOPIC	PAGE NO.
<i>TABLE 49 U.S. INCIDENCE OF HEART FAILURE AND ANNUAL HEALTHCARE COSTS, 2010 (MILLIONS/\$ BILLIONS)</i>	138
AFFOMIX CORP/UNIVERSITY OF MONTREAL PHARMACOGENOMICS CENTRE AND MONTREAL HEART INSTITUTE	139
CELERA (QUEST DIAGNOSTICS)/DECODE GENETICS	139
ROCHE/CHANTEST CORPORATION	140
CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS FOR CENTRAL NERVOUS SYSTEM DISORDERS	141
OVERVIEW	141
<i>TABLE 50 COMPANION DIAGNOSTIC TESTS FOR CENTRAL NERVOUS SYSTEM DISORDER DRUG THERAPY, 2013</i>	142
HLA-B*1502 ALLELE TESTING	142
UREA CYCLE DISORDERS TEST	142
PHYZIOTYPE PIMS	143
GENESIGHTRX	144
CURRENT COMPANION DIAGNOSTICS COMPANIES DEVELOPING COMPANION ASSAYS FOR CENTRAL NERVOUS SYSTEM DISORDERS	144
<i>TABLE 51 COMPANION DIAGNOSTICS COMPANIES DEVELOPING COMPANION ASSAYS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2013</i>	144
SALADAX BIOMEDICAL	145
CYTOX	145
DIAXONHIT	146
POPULATION DIAGNOSTICS	146
PROTAGEN	147
NEXTGEN SCIENCES	148
AMARANTUS BIOSCIENCE HOLDINGS	148
CURRENT PARTNERSHIPS BETWEEN DIAGNOSTICS COMPANIES AND THEIR PHARMACEUTICAL PARTNERS DEVELOPING COMPANION TESTS IN CENTRAL NERVOUS SYSTEM DISORDERS	149
<i>TABLE 52 PARTNERSHIPS BETWEEN DIAGNOSTICS AND PHARMACEUTICAL COMPANIES IN COMPANION DIAGNOSTICS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2010-2013</i>	149
PSYNOVA NEUROTECH/ROCHE	149
SALADAX BIOMEDICAL/BMS	150
DIAXONHIT/ALLERGEN	150
IMAGINAB/H. LUNDBECK A/S	150
KINEMED/ISIS PHARMACEUTICALS/CHDI FOUNDATION	151
DIAGENIC/MERZ PHARMACEUTICALS	151
DIAGENIC/PFIZER	151
OPKO HEALTH/BRISTOL-MYERS SQUIBB	152
ZINFANDEL PHARMACEUTICALS/TAKEDA	152
MESO SCALE DISCOVERY/BRISTOL-MYERS SQUIBB	153
SIEMENS AG/TOCAGEN	153
LUMINEX/MERCK	153
SUMMARY	154
STATISTICS, HEALTHCARE COSTS AND THE DRUG MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS AS AN ESTIMATE FOR COMPANION DIAGNOSTICS ASSAY DEVELOPMENT	154
<i>TABLE 53 U.S. STATISTICS AND HEALTHCARE COSTS OF SCHIZOPHRENIA, ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE, 2009 (\$ BILLIONS)</i>	154

TOPIC	PAGE NO.
<i>TABLE 54 U.S. REPRESENTATIVE NEURODEGENERATION DISORDER AND SCHIZOPHRENIA MARKET, 2013 (\$ BILLIONS)</i>	155
SCHIZOPHRENIA AS A MARKET FOR COMPANION DIAGNOSTIC DEVELOPMENT	155
NEURODEGENERATIVE DISORDERS AS A MARKET FOR COMPANION DIAGNOSTICS DEVELOPMENT	156
Parkinson's Disease and Current Drug Treatment	156
<i>TABLE 55 REQUIP NET SALES, 2010-2012 (\$ MILLIONS)</i>	156
CURRENT PRODUCTS FOR COMPANION DIAGNOSTIC TESTS IN INFECTIOUS DISEASES	157
OVERVIEW	157
<i>TABLE 57 COMPANION DIAGNOSTIC TESTS ON THE MARKET FOR INFECTIOUS DISEASES, 2013</i>	157
GENETIC TEST FOR HLA-B 5701	157
GENETIC TEST FOR IL28B	157
TROPISM FOR HUMAN IMMUNODEFICIENCY VIRUS ASSAY	158
<i>TABLE 58 MONOGRAM/LABCORP TROFILE SALES, 2008-2010 (MILLIONS)</i>	159
Competitors of Trofile Assay	159
<i>TABLE 59 ENTRY INHIBITOR DRUG DISCOVERY AS A NEW OPPORTUNITY FOR THE TROFILE ASSAY</i>	160
HUMAN IMMUNODEFICIENCY VIRUS DRUG-RESISTANCE TESTS	160
Human Immunodeficiency Virus Statistics and Healthcare Cost as a Factor for Companion Diagnostics Sales Forecast	161
<i>TABLE 60 U.S. HUMAN IMMUNODEFICIENCY VIRUS STATISTICS AND HEALTHCARE COSTS, 2009 (NUMBER/\$ BILLIONS)</i>	162
Human Immunodeficiency Virus Drug Market	162
<i>TABLE 61 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS DRUG MARKET, 2013 AND 2018 (\$ BILLIONS)</i>	162
CURRENT PARTNERSHIPS AND COLLABORATIONS FOR COMPANION DIAGNOSTICS FOR INFECTIOUS DISEASES	163
<i>TABLE 62 PARTNERSHIPS IN THE FIELD OF COMPANION DIAGNOSTICS FOR INFECTIOUS DISEASES BETWEEN DIAGNOSTICS AND PHARMACEUTICAL COMPANIES, 2009-2012</i>	163
MITOSCIENCES (ABCAM)/UNIVERSITY OF OREGON	164
LABCORP (MONOGRAM BIOSCIENCE)/PFIZER/SHERING PLOUGH/PROGENICS/GILEAD SCIENCE	164
ENIGMA DIAGNOSTICS/GLAXOSMITHKLINE	164
LABCORP/MERCK	165
SIEMENS HEALTHCARE DIAGNOSTICS/VIIV HEALTHCARE	165
CURRENT PRODUCTS FOR COMPANION DIAGNOSTICS IN OTHER DISEASES	166
OVERVIEW	166
<i>TABLE 63 COMPANION DIAGNOSTICS PRODUCTS IN VARIOUS CLINICAL APPLICATIONS, 2013</i>	166
ALLOMAP MOLECULAR EXPRESSION TESTING	167
HUMAN LEUKOCYTE ANTIGEN TESTING	168
COMPANION DIAGNOSTIC TEST DEVELOPMENT IN DRUG METABOLISM	169
Cytochrome P450 2C9 (CYP2C9)	169
N-acetyltransferase	169
Amplichip CYP2D6/CYP2C19	170
Serology 7 Test for Inflammatory Bowel Disease	170

TOPIC	PAGE NO.
Cholinesterase Gene Testing	171
G6PD Test	171
ImmuKnow	172
PsoriasisDX	172
FerriScan R2-MRI	173
CHAPTER 12 MARKET SUMMARY	175
<i>TABLE 64 COMPANION DIAGNOSTICS TESTS MENTIONED IN THIS REPORT</i>	175
<i>TABLE 65 COMPANION DIAGNOSTICS INDUSTRY PRODUCTS, 2013 (%)</i>	177
<i>FIGURE 7 COMPANION DIAGNOSTICS INDUSTRY PRODUCTS, 2013 (%)</i>	177
<i>TABLE 66 COMPANION DIAGNOSTICS IN THE ONCOLOGY MARKET, THROUGH 2018 (\$ MILLIONS)</i>	178
<i>FIGURE 8 COMPANION DIAGNOSTICS IN THE ONCOLOGY MARKET, 2009-2018 (\$ MILLIONS)</i>	178
<i>TABLE 67 GLOBAL COMPANION DIAGNOSTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	179
<i>FIGURE 9 GLOBAL COMPANION DIAGNOSTICS MARKET, 2011-2018 (\$ MILLIONS)</i>	179
CHAPTER 13 COMPANY PROFILES	181
ABBOTT LABORATORIES	181
BIOMERIEUX SA	182
CELERA	183
DAKO (AGILENT TECHNOLOGIES)	183
GENOMIC HEALTH INC.	184
LABCORP	185
QIAGEN N.V.	186
QUEST DIAGNOSTICS INC.	187
ROCHE DIAGNOSTICS	188
CHAPTER 14 COMPANIES MENTIONED IN THIS REPORT	190
23ANDME	190
20/20 GENE SYSTEMS	190
ABBOTT LABORATORIES	190
ADVANCED CELL DIAGNOSTICS INC.	190
AFFYMETRIX INC.	190
AGENDIA INC.	190
ALMAC GROUP	191
ALTHEADX	191
AMERITOX	191
AMGEN, INC.	191
APPLIED BIOCODE	191
ARRAYIT CORPORATION	191
ASSURERX HEALTH	192
ASURAGEN INC.	192
AUTOGENOMICS INC.	192
BECKMAN COULTER INC.	192
BG MEDICINE INC.	192
BIOCARTIS SA	192

TOPIC	PAGE NO.
BIOCRATES LIFE SCIENCES AG	193
BIOMARKER STRATEGIES	193
BIOMERIEUX SA	193
CARDIODX	193
CELERA	193
CEPHEID	193
COMPANIONDX	194
CRESCENDO BIOSCIENCE	194
CYPROTEX	194
DAKO (AGILENT TECHNOLOGIES)	194
DIAGNOCURE INC.	194
DNAVISION	194
EPIGENOMICS AG	195
FOUNDATION MEDICINE INC.	195
GENELEX CORP	195
GENMARK DIAGNOSTICS	195
GENOMAS INC.	195
GENOMIC HEALTH INC.	195
GENPROBE (HOLOGIC)	196
GSK US	196
HORIZON DISCOVERY LTD.	196
IKONISYS	196
ILLUMINA INC.	196
INTERGENETICS INC.	196
LABCORP	197
LIFE TECHNOLOGIES CORP.(THERMO FISHER SCIENTIFIC)	197
MERCK CORPORATE HEADQUARTERS	197
METABOLON INC.	197
MYRIAD GENETICS INC.	197
NANOSPHERE INC.	197
NOVARTIS INTERNATIONAL AG	198
ORION GENOMICS	198
PAMGENE INTERNATIONAL B.V.	198
PANACEA PHARMACEUTICALS	198
PATHWAY GENOMICS CORP	198
PFIZER	198
PHARMIGENE	199
PROGENIKA INC.	199
PROMETHEUS LABORATORIES INC.	199
QIAGEN N.V.	199
QUEST DIAGNOSTICS INC.	199
RESEARCHDX	199
RESPONSE GENETICS INC.	200
ROCHE DIAGNOSTICS	200
SALADAX BIOMEDICAL INC.	200
SEQUENOM INC.	200
TETHYS BIOSCIENCE	200

TOPIC	PAGE NO.
TRIMGEN CORP	200
UPSTREAM BIOSCIENCES INC	201
XDX	201

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL COMPANION DIAGNOSTICS MARKET, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 PERSONALIZED MEDICINE OVERVIEW PRODUCTS	11
TABLE 2 PERSONALIZED MEDICINE DIAGNOSTIC PRODUCTS BY SEGMENT, 2008-2018 (%)	12
TABLE 3 GLOBAL PERSONALIZED MEDICINE DIAGNOSTICS MARKET, THROUGH 2018 (\$ BILLIONS)	13
TABLE 4 COMPANION DIAGNOSTICS INDUSTRY PRODUCTS, 2013 (%)	14
TABLE 5 BIOMARKER STATISTICS IN THE DRUG DEVELOPMENT PROCESS, 2013 (%)	27
TABLE 6 GLOBAL BIOMARKER MARKET, THROUGH 2015 (\$ BILLIONS)	28
TABLE 7 GLOBAL BIOMARKERS IN VARIOUS RESEARCH AREAS, 2013 (\$ BILLIONS)	29
TABLE 8 IN VITRO DIAGNOSTICS MARKET BY REGION, 2013 (%)	32
TABLE 9 MAJOR IN VITRO DIAGNOSTICS COMPANIES, 2010 (%)	33
TABLE 10 COMPANION DIAGNOSTICS, ASSOCIATED DRUGS AND REGULATORY APPROVAL STATES, 2013	38
TABLE 11 COMPANION DIAGNOSTICS COST EXAMPLES, 2013 (\$)	39
TABLE 12 HEALTHCARE SAVINGS DUE TO COMPANION DIAGNOSTICS TESTS, 2013 (\$ MILLIONS)	41
TABLE 13 PERSONALIZED MEDICINE MARKET BY SEGMENT, 2010 AND 2015 (\$ BILLIONS)	43
TABLE 14 NUTRITION AND WELLNESS MARKET BY SECTOR, 2013 (%)	44
TABLE 15 HEALTHCARE INFORMATION TECHNOLOGY MARKET BY SECTOR, 2010 (%)	45
TABLE 16 DIAGNOSTIC AND THERAPEUTIC MARKET IN PERSONALIZED MEDICINE BY SECTOR, 2013 (%)	47
TABLE 17 PERSONALIZED MEDICINE PRODUCTS ON THE MARKET FOR THE GENERAL PUBLIC, 2013 (%)	51
TABLE 18 GLOBAL PATENT APPLICATIONS IN VARIOUS BIOMARKER RESEARCH FIELDS, 2012	54
TABLE 19 ADVANTAGES AND DISADVANTAGES OF THE MOST COMMON TECHNIQUES FOR COMPANION DIAGNOSTICS, 2013	58
TABLE 20 U.S. PHYSICIANS ORDERING COMPANION DIAGNOSTICS TESTS AS PART OF DIAGNOSIS AND TREATMENT, 2012 (%)	64
TABLE 21 U.S. PHYSICIANS' OPINIONS REGARDING THE WAYS NOVEL DRUGS WITH COMPANION DIAGNOSTICS WILL AFFECT THE USE OF CHEMOTHERAPY TREATMENT, 2012 (%)	65
TABLE 22 U.S. PHYSICIANS' OPINIONS REGARDING VARIOUS ASPECTS OF PERSONALIZED MEDICINE, 2012 (%)	66
TABLE 23 PARTICIPANTS IN THE COMPANION DIAGNOSTICS MARKET	68
TABLE 24 ACQUISITIONS OF COMPANION DIAGNOSTICS COMPANIES, 2008 TO 2013	78
TABLE 25 PARTNERSHIPS BETWEEN PHARMA AND DIAGNOSTIC COMPANIES, 2009 TO 2013	78
TABLE 26 COMPANION DIAGNOSTICS DEALS BY RESEARCH AREA, 2004-2012 (%)	81
TABLE 27 DEALS IN COMPANION DIAGNOSTICS BY SELECTED PHARMACEUTICAL PARTNERS, 2009-2012	82
TABLE 29 GLOBAL COMPANION DIAGNOSTICS MARKET, THROUGH 2018 (\$ MILLIONS)	84
TABLE 30 COMMON COMPANION DIAGNOSTICS TESTS IN CANCER APPLICATIONS, 2013	86
TABLE 31 MAIN HER2 TESTS, 2013	91
TABLE 32 KRISTEN RAS SARCOMA TEST MANUFACTURERS, 2010 (\$)	95

TABLE HEADING	PAGE NO.
TABLE 33 GLOBAL ONCOTYPEDX AND BRAC ANALYSIS MARKET, THROUGH 2018 (\$ MILLIONS)	103
TABLE 34 U.S. CANCER STATISTICS, 2013	106
TABLE 35 U.S. ANNUAL HEALTHCARE COST FOR CANCERS, AND THE AMOUNT SPENT ON SCIENTIFIC RESEARCH BY TYPE, 2010 AND 2011 (\$ BILLIONS/\$ MILLIONS)	107
TABLE 36 COST SAVINGS USING KRISTEN RAS SARCOMA COMPANION DIAGNOSTIC TEST IN COLORECTAL CANCER PATIENTS	108
TABLE 37 GLOBAL DRUGS ASSOCIATED WITH COMPANION DIAGNOSTIC TESTS, THROUGH 2018 (\$ BILLIONS)	109
TABLE 38 PARTNERSHIPS BETWEEN PHARMA AND DIAGNOSTICS COMPANIES IN ONCOLOGY, 2009 TO 2013	112
TABLE 39 COMPANION DIAGNOSTICS IN THE ONCOLOGY MARKET, THROUGH 2018 (\$ MILLIONS)	118
TABLE 40 COMPANION DIAGNOSTIC TESTS FOR METABOLIC DISEASES, 2013	119
TABLE 41 COLLABORATIONS BETWEEN COMPANION DIAGNOSTICS COMPANIES, PHARMACEUTICAL COMPANIES AND ACADEMIC INSTITUTIONS, 2008 TO 2013	124
TABLE 42 U.S. AND GLOBAL DIABETES, HYPERCHOLESTEROLEMIA AND METABOLIC SYNDROME MARKET, 2013 (MILLIONS/\$ BILLIONS)	127
TABLE 43 U.S. CARDIOVASCULAR DISEASE AND HEALTHCARE COSTS, 2010 (\$ MILLIONS/\$ BILLIONS)	129
TABLE 44 COMPANION DIAGNOSTICS FOR CARDIOVASCULAR DISEASES, 2013	129
TABLE 45 U.S. WARFARIN TREATMENT, 2010 (MILLIONS/NUMBER)	130
TABLE 46 WARFARIN SENSITIVITY TESTS BY MANUFACTURER, 2009	133
TABLE 47 GLOBAL PLAVIX MARKET, THROUGH 2012 (\$ MILLIONS)	135
TABLE 48 PARTNERSHIPS BETWEEN COMPANION DIAGNOSTICS COMPANIES, PHARMACEUTICAL COMPANIES AND ACADEMIC INSTITUTIONS IN THE CARDIOVASCULAR DISEASE SECTOR, 2007-2011	137
TABLE 49 U.S. INCIDENCE OF HEART FAILURE AND ANNUAL HEALTHCARE COSTS, 2010 (MILLIONS/\$ BILLIONS)	138
TABLE 50 COMPANION DIAGNOSTIC TESTS FOR CENTRAL NERVOUS SYSTEM DISORDER DRUG THERAPY, 2013	142
TABLE 51 COMPANION DIAGNOSTICS COMPANIES DEVELOPING COMPANION ASSAYS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2013	144
TABLE 52 PARTNERSHIPS BETWEEN DIAGNOSTICS AND PHARMACEUTICAL COMPANIES IN COMPANION DIAGNOSTICS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2010-2013	149
TABLE 53 U.S. STATISTICS AND HEALTHCARE COSTS OF SCHIZOPHRENIA, ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE, 2009 (\$ BILLIONS)	154
TABLE 54 U.S. REPRESENTATIVE NEURODEGENERATION DISORDER AND SCHIZOPHRENIA MARKET, 2013 (\$ BILLIONS)	155
TABLE 55 EQUIP NET SALES, 2010-2012 (\$ MILLIONS)	156
TABLE 57 COMPANION DIAGNOSTIC TESTS ON THE MARKET FOR INFECTIOUS DISEASES, 2013	157
TABLE 58 MONOGRAM/LABCORP TROFILE SALES, 2008-2010 (MILLIONS)	159
TABLE 59 ENTRY INHIBITOR DRUG DISCOVERY AS A NEW OPPORTUNITY FOR THE TROFILE ASSAY	160
TABLE 60 U.S. HUMAN IMMUNODEFICIENCY VIRUS STATISTICS AND HEALTHCARE COSTS, 2009 (NUMBER/\$ BILLIONS)	162
TABLE 61 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS DRUG MARKET, 2013 AND 2018 (\$ BILLIONS)	162

TABLE HEADING	PAGE NO.
TABLE 62 PARTNERSHIPS IN THE FIELD OF COMPANION DIAGNOSTICS FOR INFECTIOUS DISEASES BETWEEN DIAGNOSTICS AND PHARMACEUTICAL COMPANIES, 2009-2012	163
TABLE 63 COMPANION DIAGNOSTICS PRODUCTS IN VARIOUS CLINICAL APPLICATIONS, 2013	166
TABLE 64 COMPANION DIAGNOSTICS TESTS MENTIONED IN THIS REPORT	175
TABLE 65 COMPANION DIAGNOSTICS INDUSTRY PRODUCTS, 2013 (%)	177
TABLE 66 COMPANION DIAGNOSTICS IN THE ONCOLOGY MARKET, THROUGH 2018 (\$ MILLIONS)	178
TABLE 67 GLOBAL COMPANION DIAGNOSTICS MARKET, THROUGH 2018 (\$ MILLIONS)	179

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL COMPANION DIAGNOSTICS MARKET, 2011-2018 (\$ MILLIONS)	7
FIGURE 1 PERSONALIZED MEDICINE PRODUCTS BY SEGMENT, 2008-2018 (%)	13
FIGURE 2 COMPANION DIAGNOSTICS INDUSTRY DRIVERS	21
FIGURE 3 COMPANION DIAGNOSTICS INDUSTRY CHALLENGES	24
FIGURE 4 GLOBAL PATENT APPLICATIONS IN VARIOUS BIOMARKER RESEARCH FIELDS, 2012	54
FIGURE 5 GLOBAL ONCOTYPEDX AND BRAC ANALYSIS MARKET, 2009-2018 (\$ MILLIONS)	103
FIGURE 6 COMPANION DIAGNOSTICS IN THE ONCOLOGY MARKET, 2009-2018 (\$ MILLIONS)	118
FIGURE 7 COMPANION DIAGNOSTICS INDUSTRY PRODUCTS, 2013 (%)	177
FIGURE 8 COMPANION DIAGNOSTICS IN THE ONCOLOGY MARKET, 2009-2018 (\$ MILLIONS)	178
FIGURE 9 GLOBAL COMPANION DIAGNOSTICS MARKET, 2011-2018 (\$ MILLIONS)	179